Program
GR1803
A development code. Also written as “GR1803 injection” and “Velinotamig specified dose on specified days.”.
Its studies are mostly in Multiple Myeloma · Purpura, Thrombocytopenic, Idiopathic · Lupus Erythematosus, Systemic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Genrix Biopharmaceutical | 65 open or running | phase 3since Feb 28, 2026 | Aug 20, 2024 | May 12, 2027phase 2 · NCT06566547 |
| Cullinan Therapeutics | 11 open or running | phase 2since Jul 28, 2026 | Jul 28, 2026 | Jan 2029phase 2 · NCT07738822 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 20, 2024First study: phase 2 study in Multiple MyelomaNew to Chongqing Genrix BiopharmaceuticalChongqing Genrix Biopharmaceutical · NCT06566547 · 116 enrolled · China
- Apr 23, 2025Phase 2 study in Multiple MyleomaChongqing Genrix Biopharmaceutical · NCT06952075 · 30 planned · China
- Jul 21, 20252 phase 2 studies in Multiple MyelomaChongqing Genrix Biopharmaceutical · NCT07090954, NCT07102706
- Dec 25, 2025Phase 2 study in Lupus Erythematosus, SystemicChongqing Genrix Biopharmaceutical · NCT07348055 · 44 planned · China
- Feb 28, 2026Phase 3 study in Multiple MyelomaPhase 3 reachedChongqing Genrix Biopharmaceutical · NCT07452198 · 358 planned · China
- Jul 28, 2026Cullinan Therapeutics's first study: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNew to Cullinan TherapeuticsCullinan Therapeutics · NCT07738822 · 72 planned · United States
Ahead
- May 12, 2027Primary completion: phase 2 study in Multiple MyelomaChongqing Genrix Biopharmaceutical · NCT06566547
- Jun 1, 2027Primary completion: phase 2 study in Lupus Erythematosus, SystemicChongqing Genrix Biopharmaceutical · NCT07348055
- Jul 1, 2027Primary completion: phase 2 study in Multiple MyleomaChongqing Genrix Biopharmaceutical · NCT06952075
- Jan 2029Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicCullinan Therapeutics · NCT07738822
TargetBeta
“A Phase I Monotherapy Study Assessing the Safety and Efficacy of GR1803, a BCMA×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma”study text, by rule · the study
Other programs on CD3E
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| etentamig | AbbVie | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| cevostamab | Hoffmann-La Roche | phase 3 | 8 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| pasritamig | Johnson & Johnson | phase 3 | 5 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| gocatamig | Merck | phase 3 | 4 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 2 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07738822Purpura, Thrombocytopenic, Idiopathic · United States | 2 | Not yet recruiting | Cullinan Therapeutics | Jan 2029 | 72 |
| NCT07452198Multiple Myeloma · China | 3 | Recruiting | Chongqing Genrix Biopharmaceutical | Mar 2029 | 358 |
| NCT07348055Lupus Erythematosus, Systemic · China | 2 | Recruiting | Chongqing Genrix Biopharmaceutical | Jun 1, 2027 | 44 |
| NCT07102706Multiple Myeloma · China | 2 | Completed | Chongqing Genrix Biopharmaceutical | May 20, 2025 | 76 |
| NCT07090954Multiple Myeloma · China | 2 | Not yet recruiting | Chongqing Genrix Biopharmaceutical | Jul 31, 2026 | 32 |
| NCT06952075Multiple Myleoma · China | 2 | Recruiting | Chongqing Genrix Biopharmaceutical | Jul 1, 2027 | 30 |
| NCT06566547Multiple Myeloma · China | 2 | Active, not recruiting | Chongqing Genrix Biopharmaceutical | May 12, 2027 | 116 |
How it is read
Names in the registry
- “GR1803 injection”, 5 entries
- “Velinotamig specified dose on specified days.”, 1 entry
- “GR1803”, 1 entry
Codes read as this program: GR1803.
Conditions, from the studies’ own filings
- Multiple Myeloma, 4 studies
- Purpura, Thrombocytopenic, Idiopathic, 1 study
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.